National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda ®) is indicated as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended
Full pharmacoeconomic assessment commissioned by HSE 04/02/2018
Pre-submission consultation with Applicant 12/02/2018
Submission received from Applicant 03/10/2018
Preliminary review sent to Applicant 05/12/2018
Current status Awaiting response from Applicant